<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2718">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01496287</url>
  </required_header>
  <id_info>
    <org_study_id>CPR005027</org_study_id>
    <nct_id>NCT01496287</nct_id>
  </id_info>
  <brief_title>Tympanostomy Tube Placement in Children in the Office (Inova Study)</brief_title>
  <acronym>Inova</acronym>
  <official_title>Tympanostomy Tube Placement in Children in the Office (Inova Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acclarent</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Acclarent</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to evaluate the safety and efficacy of the Acclarent Tula TDS
      for the placement of tympanostomy tubes under local anesthesia in an office/clinic setting.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of Participants With Procedural, Serious, and Device-Related Adverse Events</measure>
    <time_frame>procedure up to 2 weeks post procedure</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Adverse events which are procedural, serious, and device-related.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Device Success</measure>
    <time_frame>Day 0 (day of procedure)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Device Success is defined as the successful delivery of the tympanostomy tube (TT) across the tympanic membrane (TM) using the Tube Delivery System(TDS). Device Success will be evaluated on a per device basis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Procedure Success</measure>
    <time_frame>Day 0 (day of procedure)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Procedure Success is defined as the successful placement of any tympanostomy tube in all enrolled ears in a given subject. Procedure Success is determined on a per subject basis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure Tolerability</measure>
    <time_frame>Day 0 (day of procedure)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Procedure Tolerability is defined as the proportion of subjects reporting the procedure as tolerable, where tolerable is defined as a score of 0 through 3, using the Wong-Baker FACES pain scale.The Wong-Baker FACES pain scoring system is a scale of 0 to 5, where 0 means 'no hurt', 1 = 'hurts a little bit', 2 = 'hurts little more', 3 = 'hurts even more', 4 = 'hurts whole lot' and 5 = 'hurts worst'. Procedure Tolerability will be determined on a per patient basis, with the patient's score being the average of the scores for the left and right ear if both ears are successfully treated with the Tube Delivery System.
&quot;Tolerability&quot; was defined as an average post-procedure pain score (of treated ears) &lt;= &quot;3&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tube Retention</measure>
    <time_frame>2 weeks post procedure</time_frame>
    <safety_issue>No</safety_issue>
    <description>Tube retention is the presence of a tympanostomy tube placed successfully by the Tula TDS device across the tympanic membrane at the two-week follow-up visit.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Otitis Media</condition>
  <arm_group>
    <arm_group_label>Tube placement group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Tube Delivery System (TDS)</intervention_name>
    <description>Placement of tympanostomy tube by the Acclarent tympanostomy tube delivery system under local anesthesia in an office/clinic setting</description>
    <arm_group_label>Tube placement group</arm_group_label>
    <other_name>Tula TDS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Scheduled to undergo tympanostomy tube insertion

          2. At least 6 months old and younger than 22 years old

          3. Behavioral capacity and cooperative temperament to undergo an awake procedure (based
             on physician judgement)

          4. No history of sensitivity or reaction to anesthesia chosen for the procedure

        Exclusion Criteria:

          1. Pregnant or lactating females

          2. Significantly atrophic, bimeric, or completely atelectatic tympanic membrane

          3. Otitis externa

          4. Lacerations or abrasions to the external auditory canal or damaged or denuded skin in
             the auditory canal

          5. Cerumen impaction resulting in a significant amount of cleaning required to visualize
             the tympanic membrane

          6. Electrically sensitive subjects and subjects with electrically sensitive support
             systems (pacemakers, defibrillators, etc.)

          7. Anatomy that precludes sufficient visualization of and access to the tympanic
             membrane

          8. Anatomy that necessitates tympanostomy tube placement in the posterior half of the
             tympanic membrane
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacob W Zeiders, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>South Coast Ear, Nose &amp; Throat</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>South Coast Ear, Nose &amp; Throat</name>
      <address>
        <city>Port St. Lucie</city>
        <state>Florida</state>
        <zip>34952</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <lastchanged_date>November 4, 2014</lastchanged_date>
  <firstreceived_date>December 16, 2011</firstreceived_date>
  <firstreceived_results_date>June 26, 2014</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Otitis Media</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Tube Placement Group</title>
          <description>Tube Delivery System (Tula): Placement of tympanostomy tube by the Acclarent tympanostomy tube delivery system following delivery of anesthetic with Acclarent iontophoresis device</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="64"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Incomplete anesthesia</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Tube Placement Group</title>
          <description>Tube Delivery System (Tula): Placement of tympanostomy tube by the Acclarent tympanostomy tube delivery system under local anesthesia in an office/clinic setting</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="70"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="7.0" spread="3.9"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="36"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="34"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>African American or Black</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="5"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Asian</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>White</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="47"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Other or Unknown</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="17"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="70"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Procedural, Serious, and Device-Related Adverse Events</title>
        <description>Adverse events which are procedural, serious, and device-related.</description>
        <time_frame>procedure up to 2 weeks post procedure</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Tube Placement Group</title>
            <description>Tube Delivery System (Tula): Placement of tympanostomy tube by the tympanostomy tube delivery system under local anesthesia in an office/clinic setting</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="70"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants With Procedural, Serious, and Device-Related Adverse Events</title>
            <description>Adverse events which are procedural, serious, and device-related.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Device Success</title>
        <description>Device Success is defined as the successful delivery of the tympanostomy tube (TT) across the tympanic membrane (TM) using the Tube Delivery System(TDS). Device Success will be evaluated on a per device basis.</description>
        <time_frame>Day 0 (day of procedure)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis population includes subjects who had completed the local anesthesia procedure (iontophoresis) and in which a TDS tube delivery device was attempted.</population>
        <group_list>
          <group group_id="O1">
            <title>Tube Placement Group</title>
            <description>Tube Delivery System (Tula): Placement of tympanostomy tube by the tympanostomy tube delivery system under local anesthesia in an office/clinic setting</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="65"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of devices analyzed</title>
            <units>devices</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="128"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Device Success</title>
            <description>Device Success is defined as the successful delivery of the tympanostomy tube (TT) across the tympanic membrane (TM) using the Tube Delivery System(TDS). Device Success will be evaluated on a per device basis.</description>
            <units>devices</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="114"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Procedure Success</title>
        <description>Procedure Success is defined as the successful placement of any tympanostomy tube in all enrolled ears in a given subject. Procedure Success is determined on a per subject basis.</description>
        <time_frame>Day 0 (day of procedure)</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Tube Placement Group</title>
            <description>Tube Delivery System (Tula): Placement of tympanostomy tube by the Acclarent tympanostomy tube delivery system under local anesthesia in an office/clinic setting</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="70"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Procedure Success</title>
            <description>Procedure Success is defined as the successful placement of any tympanostomy tube in all enrolled ears in a given subject. Procedure Success is determined on a per subject basis.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="63"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Procedure Tolerability</title>
        <description>Procedure Tolerability is defined as the proportion of subjects reporting the procedure as tolerable, where tolerable is defined as a score of 0 through 3, using the Wong-Baker FACES pain scale.The Wong-Baker FACES pain scoring system is a scale of 0 to 5, where 0 means 'no hurt', 1 = 'hurts a little bit', 2 = 'hurts little more', 3 = 'hurts even more', 4 = 'hurts whole lot' and 5 = 'hurts worst'. Procedure Tolerability will be determined on a per patient basis, with the patient’s score being the average of the scores for the left and right ear if both ears are successfully treated with the Tube Delivery System.
&quot;Tolerability&quot; was defined as an average post-procedure pain score (of treated ears) &lt;= &quot;3&quot;</description>
        <time_frame>Day 0 (day of procedure)</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Tube Placement Group</title>
            <description>Tube Delivery System (Tula): Placement of tympanostomy tube by the Acclarent tympanostomy tube delivery system under local anesthesia in an office/clinic setting</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="64"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Procedure Tolerability</title>
            <description>Procedure Tolerability is defined as the proportion of subjects reporting the procedure as tolerable, where tolerable is defined as a score of 0 through 3, using the Wong-Baker FACES pain scale.The Wong-Baker FACES pain scoring system is a scale of 0 to 5, where 0 means 'no hurt', 1 = 'hurts a little bit', 2 = 'hurts little more', 3 = 'hurts even more', 4 = 'hurts whole lot' and 5 = 'hurts worst'. Procedure Tolerability will be determined on a per patient basis, with the patient’s score being the average of the scores for the left and right ear if both ears are successfully treated with the Tube Delivery System.
&quot;Tolerability&quot; was defined as an average post-procedure pain score (of treated ears) &lt;= &quot;3&quot;</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="59"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tube Retention</title>
        <description>Tube retention is the presence of a tympanostomy tube placed successfully by the Tula TDS device across the tympanic membrane at the two-week follow-up visit.</description>
        <time_frame>2 weeks post procedure</time_frame>
        <safety_issue>No</safety_issue>
        <population>Only 62 of the initial 70 subjects achieved procedure success, and were present for 2 week follow-up assessment with Tula tube in situ, such that tube retention could be measured.</population>
        <group_list>
          <group group_id="O1">
            <title>Tube Placement Group</title>
            <description>Tube Delivery System (Tula): Placement of tympanostomy tube by the Acclarent tympanostomy tube delivery system under local anesthesia in an office/clinic setting</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="62"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of ears analyzed</title>
            <units>ears</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="112"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Tube Retention</title>
            <description>Tube retention is the presence of a tympanostomy tube placed successfully by the Tula TDS device across the tympanic membrane at the two-week follow-up visit.</description>
            <units>ears</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="111"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>procedure through 2 weeks post-procedure</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Tube Placement Group</title>
          <description>Tube Delivery System (Tula): Placement of tympanostomy tube by the Acclarent tympanostomy tube delivery system under local anesthesia in an office/clinic setting</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>occluded tube</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>otalgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director of Clinical Research</name_or_title>
      <organization>Acclarent, Inc.</organization>
      <phone>650-687-5888</phone>
      <email>lenglan1@its.jnj.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
